Status:
UNKNOWN
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Novartis
Conditions:
Glaucoma
Ocular Surface Disease
Eligibility:
All Genders
Brief Summary
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
Detailed Description
To assess glaucoma patients' response to treatment with Xiidra (Lifitegrast ophthalmic solution) 5% for ocular surface discomfort caused, in part, by topical glaucoma antihypertensive medications.
Eligibility Criteria
Inclusion
- Currently using one or more topical glaucoma antihypertensives
- Self-described symptoms of ocular surface discomfort
- Xiidra is being prescribed as part of the subject's standard care
Exclusion
- History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
- current use of topical cyclosporine
- current use of topical steroids
- incisional ocular surgery within 6 months
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04354545
Start Date
April 1 2021
End Date
June 1 2024
Last Update
November 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Doheny Eye Center UCLA
Fountain Valley, California, United States, 92708